CRMD — CorMedix Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $7.38
- 30-Day Move
- -35.8%
- Market Cap
- $557M
- Shares Outstanding
- 79,050,000
- P/E Ratio
- 3.42
- P/B Ratio
- 2.26
CorMedix Inc
A read-only Alphactor snapshot forCorMedix Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$7.38
30-Day Move
-35.8%
Market Cap
$557M
Shares Outstanding
79,050,000
P/E Ratio
3.42
P/B Ratio
2.26
$7.38
-35.8%last 90 delayed daily bars
90D High
$13.02
90D Low
$6.13
Avg Volume
2,209,852
Gross margin is running at 88.5%, which gives a quick read on operating quality before you open the full model.
Net margin is 52.3%, useful for comparing CRMD against peers in Pharmaceuticals.
CRMD is down 35.8% over the last 30 trading days shown on this page.
Latest operating income is $59M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$95.66
Rule of 40
672.5%
Latest Close
$7.38
30-Day Move
-35.8%
Market Cap
$557M
Shares Outstanding
79,050,000
P/E Ratio
3.42
P/B Ratio
2.26
ROE
40.2%
ROA
19.7%
Gross Margin
88.5%
Operating Margin
48.2%
Net Margin
52.3%
Debt / Equity
0.36
Current Ratio
2.11
Latest Revenue
$129M
Revenue
$129M
Gross Profit
$107M
Operating Income
$59M
Net Income
$14M
Gross Margin
8846.0%
Net Margin
5231.0%
Current Ratio
2.11
Debt / Equity
0.36
Fair Value
$95.66
Upside / Downside
+1196.2%
Signal
Undervalued
Implied Growth
-19.5%
DCF
$171.66
EV/Rev
$19.66
Growth Assumption
50.0%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$173M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
1.75
Distress
Piotroski
5
Moderate (4-6)
Cash Conversion
1.07x
Rule of 40
672.5%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $65,408 | $-31M | $-30M | $-25M |
| 2023-12-31 | $0 | $-49M | $-46M | $-39M |
| 2024-12-31 | $43M | $-22M | $-18M | $-51M |
| 2025-12-31 | $312M | $150M | $163M | $173M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$275,500
Sell Value
$5M
Buys
1
Sells
14
Buy Value
$275,500
Sell Value
$5M
Buy/Sell Ratio
0.07x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-04 | Zelnick Kaufman Beth | A | 36,006 | $0.00 |
| 2026-02-04 | Hurlburt Elizabeth | A | 36,006 | $0.00 |
| 2026-02-04 | Todisco Joseph | A | 77,156 | $0.00 |
| 2026-01-26 | Stewart Robert A | A | 30,453 | $0.00 |
| 2026-01-26 | Dillione Janet | A | 30,453 | $0.00 |
| 2026-01-26 | Kaplan Myron | A | 30,453 | $0.00 |
| 2026-01-26 | Duncan Gregory Scott | A | 30,453 | $0.00 |
| 2026-01-26 | Lefkowitz Steven W | A | 30,453 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,227,723 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,822,295 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 794,133 | 0.01% | 2025-12-31 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 785,700 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 721,481 | 0.01% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | 619,056 | 0.01% | 2026-02-28 |
| World Funds Trust-Applied Finance Explorer Fund | 544,221 | 0.01% | 2026-01-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 464,955 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2026-02-17
--
--
Vanguard Group
Filed 2025-08-11
$53M
+18.6%
Marshall Wace
Filed 2025-11-13
$40M
--
Geode Capital Management
Filed 2026-02-09
$22M
+5.7%
Citadel Advisors
Filed 2025-08-14
$21M
--
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.